Nonocclusive mesenteric ischemia
Executive Summary
Nonocclusive mesenteric ischemia (NOMI) is a life-threatening condition characterized by a sudden reduction in intestinal blood flow due to primary mesenteric arterial vasoconstriction, not a physical blockage. It most commonly occurs in critically ill patients experiencing systemic hypoperfusion from conditions such as heart failure, sepsis, or shock. A high degree of clinical suspicion is essential for diagnosis, as symptoms are often nonspecific and can be masked by the patient's underlying critical illness.
Definitive diagnosis relies on selective mesenteric arteriography, which can identify characteristic vascular spasms. However, computed tomography (CT) angiography is a critical screening tool. The primary treatment goal is the rapid restoration of intestinal blood flow. This involves aggressive hemodynamic support, treating the underlying precipitating conditions, and removing inciting factors like vasoconstrictive medications. Intra-arterial infusion of vasodilators, such as papaverine, is a key therapeutic option. Surgical exploration and bowel resection are reserved for patients who develop peritonitis or bowel infarction. Despite advances in intensive care, NOMI carries an extremely high mortality rate of 70 to 90 percent, largely attributable to the severity of comorbid conditions and diagnostic delays.
I. Overview and Pathophysiology
A. Definition
Nonocclusive mesenteric ischemia (NOMI) is a form of acute mesenteric ischemia defined by the sudden onset of intestinal hypoperfusion resulting from a nonocclusive decrease in arterial blood flow. The underlying mechanism is a primary spasm or vasoconstriction of the mesenteric arteries, particularly the superior mesenteric artery (SMA) and its branches. This condition was first described in patients with heart failure.
B. Pathophysiology
The development of NOMI is linked to a systemic homeostatic response that prioritizes blood flow to the heart and brain during periods of low cardiac output, at the expense of mesenteric and peripheral circulation.
Mediators: Neurohormonal mediators, specifically vasopressin and angiotensin, are likely key drivers of this intense vasoconstriction.
Triggers: Spasm can also be initiated by other vasoactive and cardiotonic drugs.
Intestinal Resilience: The intestine possesses a compensatory mechanism, allowing it to withstand a 75 percent acute reduction in mesenteric blood flow for up to 12 hours without substantial injury, primarily through increased oxygen extraction. Ischemia develops when the delivery of oxygen and nutrients becomes insufficient for cellular metabolism.
C. Relevant Anatomy
The blood supply to the small and large intestines is derived primarily from the superior mesenteric artery (SMA) and inferior mesenteric artery (IMA).
Superior Mesenteric Artery (SMA): Supplies the small intestine (jejunum, ileum), cecum, appendix, ascending colon, and proximal portion of the transverse colon. Its branches include the inferior pancreaticoduodenal, middle colic, right colic, ileocolic, jejunal, and ileal arteries.
Inferior Mesenteric Artery (IMA): Supplies blood from the distal transverse colon to the upper rectum.
Collateral Circulation: An extensive network of collateral vessels exists between the SMA, IMA, and internal iliac arteries. Key connections include the arc of Riolan (at the base of the mesentery) and the marginal artery of Drummond (along the mesenteric border). Despite this, certain "watershed areas" like the splenic flexure and rectosigmoid junction are more vulnerable to ischemia during systemic hypotension.
Venous Drainage: The venous system, including the superior mesenteric vein (SMV) and inferior mesenteric vein (IMV), runs parallel to the arterial supply and drains into the portal vein.
II. Epidemiology and Risk Factors
A. Prevalence
NOMI accounts for 5 to 15 percent of all cases of acute mesenteric ischemia. In mixed patient populations with intestinal gangrene, the proportion attributable to NOMI is reported to be between 4 and 60 percent.
B. Incidence Trends
The incidence of NOMI has declined by approximately 50 percent since the 1970s. This reduction is attributed to advancements in intensive care, including:
Widespread use of invasive hemodynamic monitoring.
Prompt correction of hypotension.
More judicious use of systemic vasodilators in managing cardiac failure.
Despite this decline, NOMI, when it occurs, results in high mortality rates due to diagnostic difficulty and the severity of underlying illnesses. A study analyzing data from 1970 to 1982 estimated the incidence of NOMI with intestinal infarction at 2.0 per 100,000 person-years.
C. Key Risk Factors
NOMI typically affects critically ill patients with severe cardiovascular disease or other life-threatening conditions. A careful review of the patient's medical history is crucial.
III. Clinical Presentation and Diagnosis
Diagnosis of NOMI depends on a high degree of clinical suspicion, particularly in patients with known risk factors, because signs and symptoms are nonspecific and often obscured by the patient's critical illness.
A. History and Physical Examination
Abdominal Pain: The pain accompanying NOMI is typically more variable than the classic "pain out of proportion to physical exam" seen in acute mesenteric arterial obstruction. It often begins as mild, nonspecific abdominal pain that gradually progresses.
Associated Symptoms: Bloating, nausea, and vomiting may be present.
Absence of Pain: Abdominal pain is absent in up to 25 percent of patients.
Masked Presentation: The clinical picture can be overshadowed by precipitating disorders like congestive heart failure, hypotension, or cardiac arrhythmias. Many patients are intubated and sedated, further masking clinical signs.
Mental Status Changes: Reported to occur in approximately one-third of older adult patients.
Physical Findings: The abdominal examination may be normal initially or show only mild distension or occult blood in the stool. Signs of peritoneal inflammation, such as rebound tenderness and guarding, are late findings that signal transmural bowel infarction and impending perforation.
B. Laboratory Studies
Laboratory findings in NOMI are nonspecific and cannot definitively establish the diagnosis, but they may bolster suspicion.
Common Abnormalities: Elevated white cell count, elevated serum lactate, elevated hematocrit (due to hemoconcentration), and metabolic acidosis.
Diagnostic Limitation: A patient with acute abdominal pain, minimal physical findings, an abnormal abdomen on exam, and metabolic acidosis should be suspected of having intestinal ischemia until proven otherwise. However, normal laboratory values do not exclude the diagnosis.
C. Imaging Studies
Plain Abdominal Films and Ultrasound
These modalities have a limited role in diagnosing NOMI and can be normal in over 25 percent of cases. Their primary utility is in helping to exclude other causes of abdominal pain. Findings suggestive of advanced ischemia include:
Ileus (distended, featureless loops of small bowel)
Bowel wall thickening
Portovenous gas
Pneumatosis intestinalis (air within the bowel wall)
Cross-Sectional Abdominal Imaging (CT/MRI)
CT Angiography (CTA): This is the preferred first-line imaging study for patients with suspected acute mesenteric ischemia. It should be performed without oral contrast, which can obscure the mesenteric vessels. CTA is useful for screening patients and identifying features consistent with an alternative diagnosis.
Findings Consistent with Ischemia: Focal or segmental bowel wall thickening, bowel dilation, mesenteric stranding, or intestinal pneumatosis with portal vein gas.
Magnetic Resonance (MR) Imaging: Generally used less often than CT due to lower availability and higher costs.
Definitive Diagnosis: Arteriography
Selective Mesenteric Arteriography: This invasive procedure provides the greatest advantage in diagnosing NOMI. It allows for the direct visualization of the mesenteric vasculature.
Characteristic Findings:
Demonstration of narrowing or spasm of the mesenteric arcades.
Reduced number of mesenteric vessels (arteries and veins).
Irregularity of the arterial vasculature, creating an appearance described as a "chain of lakes" or "string of sausages".
Diffuse spasm of all arteries in the abdomen (hepatic, splenic, renal, mesenteric) can also be seen on an aortogram.
Limitations: The spasm may be relieved by the procedure itself, potentially leading to a missed diagnosis.
IV. Treatment and Management
The overarching goal of treatment is to restore intestinal blood flow as quickly as possible. Management involves a multi-pronged approach targeting hemodynamic stability, underlying causes, and direct vasodilation.
A. Hemodynamic Support and Monitoring
Patients suspected of having NOMI require immediate resuscitation and intensive monitoring.
Measures: Correction of cardiac function, improvement of circulating volume, correction of metabolic acidosis, and initiation of broad-spectrum antibiotics (due to high risk of bacterial translocation).
Decompression: Placement of a nasogastric tube for gastric decompression.
Inotropes: Vasoconstricting agents should be avoided if possible. If an inotropic agent is necessary, dobutamine or milrinone are preferred over other vasopressors.
B. Vasodilator Infusion
Other than supportive care, this is the only intervention specifically available for NOMI.
Administration: Vasodilators are administered via an arteriographic catheter placed directly into the superior mesenteric artery.
Primary Agent: Papaverine is the predominantly used agent. Prostaglandins and nitroglycerin are other options.
Efficacy: While not supported by robust, randomized trials, evidence from case reports and a small retrospective series suggests that earlier initiation of vasodilator therapy is associated with a higher likelihood of survival.
Follow-up: Repeat arteriography can be performed in 24 hours in patients without peritoneal signs to verify the resolution of vasoconstriction.
C. Anticoagulation
The role of systemic anticoagulation for NOMI is not supported by evidence from any clinical trials. While some clinicians use it to limit vasoconstriction, this practice is not standard.
D. Abdominal Exploration (Surgery)
Surgical intervention is indicated for patients who develop signs of peritonitis, which suggests bowel infarction or perforation.
Timing: Surgery should not be delayed in patients with peritoneal signs.
Procedure: The operation involves bowel resection for nonviable segments and completion of intestinal anastomosis.
Second-Look Operation: An aggressive re-exploration or "second-look" laparotomy is often planned to re-evaluate the viability of the remaining bowel. In one series, this approach improved survival (42 percent vs 22 percent).
Assessment Tools: Intraoperative assessment of adequate intestinal perfusion may be aided by indocyanine green (ICG) fluorescence.
V. Morbidity and Mortality
NOMI is associated with the poorest survival rate among all etiologies of mesenteric ischemia. The mortality rate remains exceptionally high, ranging from 70 to 90 percent. This poor prognosis has changed little over time and is primarily a reflection of the severity of the patients' underlying comorbid conditions and significant delays in establishing a diagnosis.
